What happened with CLYM today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Climb Bio is a clinical-stage biotechnology company developing treatments for diseases driven by the immune system. Its business centers on budoprutug, being studied for autoimmune kidney disease, immune thrombocytopenia and lupus, and CLYM116, being developed for IgA nephropathy, a kidney disease. It has no revenue and funds its work primarily with money raised from investors. Future drug sales depend on successful development and regulatory approval; coverage and reimbursement by healthcare payers would also affect revenue.
The company relies on licensed rights to both candidates. Its budoprutug rights from CRH exclude cancer treatment, while its CLYM116 license from Mabworks covers commercialization outside Greater China. These agreements require development progress and milestone and royalty payments, and failure to meet their obligations can cost Climb Bio its rights. It also relies on outside manufacturers for drug supply.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Climb Bio’s prospects hinge on budoprutug and CLYM116 showing clinical advantages, with Mabworks supplying CLYM116’s licensed intellectual property and Otsuka’s approved sibeprenlimab setting a key competitive benchmark.
Jade Biosciences’ JADE101 competes with Climb Bio’s CLYM116 as an antibody targeting APRIL to treat IgA nephropathy. Watch JADE101’s clinical results: Jade’s claims of stronger APRIL binding remain preclinical, and it has no clinical data in IgA nephropathy.
Vera Therapeutics’ atacicept competes with Climb Bio’s CLYM116 in IgA nephropathy, and both develop treatments for autoimmune kidney diseases. Atacicept met its Phase 3 primary endpoint at week 36, and Vera’s November 2025 U.S. application for accelerated approval in adults with IgA nephropathy is a concrete competitive milestone to watch.
Zenas BioPharma’s obexelimab offers a competing CD19-directed approach to the autoimmune diseases Climb Bio pursues with budoprutug. Zenas has licensed development and sales rights to BMS in Japan, South Korea, Taiwan, Singapore, Hong Kong and Australia, while retaining commercialization rights elsewhere.
Cullinan Therapeutics’ CLN-978 competes with Climb Bio’s budoprutug by directing T cells toward CD19-bearing B cells to treat autoimmune disease. Watch whether clinical results support Cullinan’s proposed advantages of broader B-cell depletion and use without lymphodepleting chemotherapy.
Cabaletta Bio’s engineered T-cell therapies compete for the B-cell-mediated autoimmune diseases Climb Bio targets with budoprutug. Its clinical progress matters as a test of this alternative treatment approach; Cabaletta has not generated product-sales revenue and says approval may never come.
Kyverna Therapeutics’ engineered T-cell treatments, known as CAR-T therapies, compete with Climb Bio’s budoprutug in autoimmune disease. Watch KYV-102’s manufacturing progress: Kyverna intends its whole-blood process to avoid apheresis collection and shorten production time compared with conventional CAR-T products.
Nkarta’s NKX019 competes with Climb Bio’s budoprutug by using engineered natural killer cells targeting CD19 to treat autoimmune diseases. Its donor-derived cells are frozen in individual doses for clinical sites to thaw, making NKX019 an off-the-shelf cell-therapy alternative whose clinical results are worth watching.
Novartis’ anti-APRIL antibody zigakibart is both a direct rival and a benchmark for Climb Bio’s CLYM116 in IgA nephropathy. Watch zigakibart’s clinical results when judging whether CLYM116’s preclinical APRIL clearance and antibody recycling translate into a treatment advantage.
Amgen’s marketed CD19 antibody UPLIZNA gives Climb Bio’s budoprutug an established competitor and commercial benchmark. UPLIZNA’s adoption in its approved NMOSD, IgG4-RD and gMG uses is the product-level signal to watch, rather than Amgen’s overall medicine sales.
Travere Therapeutics’ FILSPARI already competes for treatment spending in IgA nephropathy, the market Climb Bio targets with CLYM116. Watch uptake of this once-daily oral, non-immunosuppressive medicine, which Travere says significantly slowed kidney-function decline in a Phase 3 trial against an active, maximally titrated renin-angiotensin system inhibitor.
Biohaven’s BHV-1400 is a competing protein-degradation approach for IgA nephropathy, the disease Climb Bio targets with CLYM116. Watch BHV-1400’s development as an alternative to Climb’s anti-APRIL antibody; Biohaven has prioritized extracellular protein-degradation platforms for immunological diseases.
Biogen’s felzartamab competes with Climb Bio’s CLYM116 in IgA nephropathy through a different target, CD38, and Biogen also develops treatments for primary membranous nephropathy, another market Climb pursues. Felzartamab’s IgA nephropathy results are the relevant competitive signal, rather than Biogen’s multiple-sclerosis medicine sales.
Artiva Biotherapeutics’ AlloNK offers a competing cell-based treatment for autoimmune diseases against Climb Bio’s antibody approach to controlling disease-causing B cells. Watch AlloNK’s clinical progress and manufacturing consistency: Artiva reports producing more than 50 clinical batches with consistency across batches and donors.
Novartis AG earningsNVS
If Novartis reports clinical progress for zigakibart, its results will show whether another anti-APRIL treatment is showing clinical benefit in IgA nephropathy—and set a benchmark for Climb Bio's CLYM116.
Look for any reported zigakibart results in IgA nephropathy and whether they support a clinical benefit. Clear evidence of benefit would show that an anti-APRIL approach can move beyond biological rationale to help patients, raising the bar for CLYM116. Disappointing results or setbacks would make zigakibart a less established rival, but would not show whether CLYM116 works.
Fed Interest Rate Decision
Climb Bio’s policy-rate decision matters because it can change the yield on cash and marketable securities the company reinvests, affecting interest income that helps offset its research and development and other operating costs.
Expected4.0%Last release4.0%
If it comes in above expectations
Higher rates may lift yields as Climb Bio reinvests its cash and securities, increasing interest income available to help cover operating costs; the benefit depends on the yields it can obtain.
If it comes in below expectations
Lower rates may reduce yields as Climb Bio reinvests its cash and securities, leaving less interest income to help cover operating costs.
Travere Therapeutics, Inc. earningsTVTX
Travere Therapeutics' report will show how FILSPARI is being taken up for IgA nephropathy, revealing whether patients and prescribers are adopting treatment in a market Climb Bio hopes to enter.
Look at any disclosed FILSPARI sales or uptake. Expanding use would show that patients and prescribers are adopting treatment for IgA nephropathy, while an already marketed medicine reaches more potential patients and competes for treatment choices Climb Bio hopes to serve. Weak uptake would point to possible access, prescribing, or acceptance hurdles—not prove that patients have no need for treatment.
Cullinan Therapeutics, Inc. earningsCGEM
If Cullinan Therapeutics reports clinical results for CLN-978, they will show whether its proposed broader B-cell depletion and avoidance of pre-treatment chemotherapy can make it a credible alternative to Climb Bio's budoprutug.
Look for clinical evidence behind Cullinan's two proposed advantages for CLN-978: broader B-cell depletion and avoiding chemotherapy to clear immune cells before treatment. If results support both, CLN-978 becomes a more credible autoimmune treatment alternative and a stronger competitor for budoprutug. If they do not, or the program hits setbacks, those advantages remain unproven in patients.
Climb Bio, Inc. earningsThis company
Climb Bio has no product-sales revenue, so this report will show whether spending on budoprutug and CLYM116 is advancing its programs—and how quickly cash is being used.
Read research and development spending on budoprutug and CLYM116 alongside operating cash use and the cash and marketable securities balance. More investment with disclosed trial progress, while cash use stays controlled, would show Climb Bio is advancing its programs with a buffer still in place. Rising cash use without much disclosed progress would thin that buffer and make future funding more pressing.
